UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of

UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation
for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular
                                     Hole

  PR Newswire

  LEUVEN, Belgium, September 2, 2013

LEUVEN, Belgium, September 2, 2013 /PRNewswire/ --

    Metamorphopsia confirmed as a severe and distressing symptom deserving
          immediate attention and early treatment with reimbursement

  *NICE FAD recommending reimbursement of JETREA for treatment of VMT
    patients, from early stage to late-stage (full thickness macular hole
    (FTMH) < 400 microns), when severe and distressing symptoms; patients with
    ERMs are excluded
  *NICE FAD recommending reimbursement of JETREA for treatment of patients
    showing symptoms of metamorphopsia (blurred vision); metamorphopsia
    patient impact considered severe and distressing, and equal to loss of 2
    lines in visual acuity
  *Confirmation of reimbursement for patients suffering from VMT with FTMH <
    400 microns

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused
on developing and commercializing innovative ophthalmic medicines, announces
that the UK's National Institute for Health and Care Excellence (NICE) has
confirmed, in its Final Appraisal Determination (FAD), its recommendation that
JETREA ^® (ocriplasmin) is an innovative new treatment and should be
reimbursed within the National Health Service (NHS) in England and Wales.

The NICE FAD confirms NICE's earlier Appraisal Consultation Document (ACD),
which initially recommended JETREA ^® as an option for treating vitreomacular
traction (VMT) in adults, including when associated with a macular hole of
less than or equal to 400microns, when patients have severe symptoms and an
epiretinal membrane is not present.

In its Final Appraisal Determination, NICE for the first time also
characterized metamorphopsia as a 'severe and distressing' symptom with its
impact on the patient being comparable to a loss of 2 lines in visual acuity.

As a result, NICE not only recommends full reimbursement of JETREA ^® for
patients with VMT and FTMH, smaller or equal to 400 microns, it also
recommends reimbursement for those VMT patients with early stage VMT symptoms
including metamorphopsia. 

There are no other pharmacological treatments in development for the treatment
of VMT. Currently patients either have to watch and wait before they are
considered eligible for surgery. Surgery is only performed at a later stage of
a patient's disease, once symptoms progress and their sight deteriorates
significantly. 

Dr Patrik De Haes, CEO of ThromboGenics , said:

"This further endorsement from UK NICE is great news for ensuring that
physicians, who are treating patients with VMT and macular hole, will have
access to  JETREA ^® , the first and only pharmacological treatment for this
progressive disease.

"We feel highly encouraged by the NICE FAD confirming that metamorphopsia is a
'severe and distressing' symptom that requires immediate treatment, and that
an early treatment with J ETREA ^®  should be reimbursed by the NHS.

"There is growing evidence that prolonged VMT may lead to progressive loss of
vision and increase a risk that subsequent intervention may be less
successful. From our own market research, we also know that a high number of
retina specialists feel that patients presenting themselves with
metamorphopsia should be treated. With JETREA ^® , patients, could for the
first time, be offered a reimbursed alternative to watchful waiting, meaning
they will no longer have to wait until symptoms progress and vision
deteriorates.  We look forward to final NICE guidance later this year." 

JETREA ^® is the first and only pharmacological treatment indicated for use in
patients diagnosed with VMT and macular hole of diameter less than or equal to
400 microns and was approved in the European Union by the European Commission
in March 2013. Alcon, a division of Novartis, acquired the rights to
commercialize JETREA ^® outside the United States in March 2012. In April,
Alcon launched JETREA ^® in the UK, its first market in Europe, resulting in
ThromboGenics receiving €90 million in milestone payments.

The FAD is the last step in the appraisal process before final guidance on the
reimbursement of JETREA ^® is issued to the NHS in England and Wales. Final
NICE guidance is expected later this year.

JETREA ^® contains the active substance ocriplasmin. It is administered
through a single intravitreal injection to treat adults with vitreomacular
traction (VMT).

VMT is a progressive, sight-threatening condition. It is caused by the
vitreous humour having an abnormally strong attachment to the macula, the
central part of the retina (the light sensitive membrane at the back of the
eye). The macula provides central vision that is needed for everyday tasks
such as driving, reading and recognizing faces.

When the vitreous humor shrinks, the strong attachment results in a pulling
force on the retina, which may lead to visual distortion, decreased visual
acuity and central blindness. When the disease progresses the traction may
eventually result in the formation of a hole in the macula (called a macular
hole).

JETREA ^® breaks down the protein fibers which cause the abnormal traction
between the vitreous and the macula that causes VMT. By dissolving these
proteins, JETREA ^® releases the traction, and helps to complete the
detachment of the vitreous from the macula.

JETREA ^® can also be used when VMT has progressed and caused a small hole in
the macula (central part of the light-sensitive layer at the back of the eye).

The current approach in the EU is 'observation', 'watchful waiting' or 'watch
and wait' until a patient becomes a candidate for surgical treatment, usually
at a late stage of the disease. ^[ ^1 ^] ^, ^[ ^2 ^] A patient would then
receive a surgical procedure and repair of the retina. However, for many
patients this is not a suitable option, as irreversible damage to the retina
may have already occurred. ^[ ^3 ^] ^, ^[ ^4 ^]

ThromboGenics is continuing to work closely with Alcon to ensure patients
across Europe and rest of the world can access this innovative medicine and
receive JETREA ^® as soon as it becomes available in the respective countries.

References

^[ ^1 ^] ^. Idiopathic macular hole. American  Academy  of  Ophthalmology ;
2008

^[ ^2 ^] ^. Stalmans P. Management and intervention strategies for symptomatic
vitreomacular adhesions. Retinal Physician 2011

^[ ^3 ^] ^. Koerner F & Garweg J. Vitrectomy for macular pucker and
vitreomacular traction syndrome. Doc Ophthalmol 1999;97:449-458

^[ ^4 ^] ^. Dugel PU, Brown DM, Humayun MS et al . Symptomatic vitreomacular
adhesion: diagnosis, pathologic implications, and management. Retina Today
2011;(Suppl):1-14

About  JETREA ^® (ocriplasmin)

JETREA ^® (ocriplasmin) is a truncated form of human plasmin. In the US,
JETREA ^® is indicated for the treatment of symptomatic VMA. In Europe, JETREA
^® is indicated for the treatment of vitreomacular traction (VMT), including
when associated with macular hole of diameter ≤ 400 microns. JETREA ^® is a
selective proteolytic enzyme that cleaves fibronectin, laminin and collagen,
three major components of the vitreoretinal interface that play an important
role in vitreomacular adhesion.

JETREA ^® has been evaluated in two multi-center, randomized, double-masked
Phase III trials conducted in the U.S. and Europe involving 652 patients with
vitreomacular adhesion. Both studies met the primary endpoint of resolution of
VMA at day 28.

JETREA's Phase III program found that 26.5% of patients treated with
ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving
placebo (p<0.01). The Phase III program also showed that JETREA was generally
well tolerated with most adverse events being transient and mild in severity.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The
Company's lead product, JETREA ^® (ocriplasmin), has been approved by the US
FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the
commercialization of JETREA ^® outside the United States. Under this
agreement, ThromboGenics could receive up to a total of €375 million in
up-front and milestone payments. It will receive significant royalties from
Alcon's net sales of JETREA ^® . ThromboGenics and Alcon intend to share the
costs equally of developing JETREA ^® for a number of new vitreoretinal
indications.

In Europe, JETREA ^® is approved for the treatment of vitreomacular traction
(VMT), including when associated with macular hole of diameter less than or
equal to 400 microns. Alcon has launched JETREA ^® in the UK, Germany,
Finland, Norway and Sweden. 

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor),
also referred to as TB-403, for the treatment of ophthalmic and oncology
indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available at
http://www.thrombogenics.com .

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction.  No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

For further information please contact: Thrombogenics Wouter Piepers, Global
Head of Corporate Communications +32-16-75-13-10 / +32-478-33-56-32
Wouter.piepers@thrombogenics.com Dr. Patrik De Haes, CEO +32-16-75-13-10
Patrik.dehaes@thrombogenics.com Chris Buyse, CFO +32-16-75-13-10
Chris.buyse@thrombogenics.com Citigate Dewe Rogerson David Dible/ Nina
Enegren/ Sita Shah Tel: +44-20-7638-9571  sita.shah@citigatedr.co.uk The
Trout Group (US investor relations) Todd James/ Simon Harnest Tel:
+1-646-378-2926 tjames@troutgroup.com